中国生物产业大会网

Zihe Rao, President of Nankai University， a Member of the Chinese Academy of Sciences, and also holds the following positions: Deputy of the National People’s Congress; Standing Committee Member of the China Association for Science and Technology; President of the Biophysical Society of China; a Council Member of the International Union for Pure and Applied Biophysics (IUPAB); Boad Member of the National Basic Science Research Program （“973”） and Chairman of the Frontier Science Group; and Chairman of the National Key Research Program（2006-2020）：“Protein Research Plan”.

Professor Rao’s major research focus involves the structure, function and innovative drug discovery targeting important virus- and tumor-related proteins. Professor Rao has achieved a number of major research results in this area, with significantcontributions relating to the SARS coronavirus, the influenza virus, and the mitochondrial respiratory membrane protein Complex II. To date, he has published 236 articles in international scientific journals, with 13 articles in the Nature/Cell publishing groups, including 3 Nature papers and 2 Cell papers. His total number of citations exceeds 2,000. Professor Rao has also applied for 18 innovation patents.

Professor Rao was honored with the Qiushi Outstanding Young Scholar Award in 1999; the He-Liang-He-Li Foundation Science and Technology Prize in 2003; the Chen Jiageng Science Prize for Life Science in 2006; the highest award from the Third World Academy of Science, the Trieste Science Prize, in 2006; and the first Life Achievement Prize from the Tan Jia-Zhen Awards for Life Sciences. Professor Rao was elected Member of the Chinese Academy of Sciences in 2003, and a Member of the Third World Academy of Science in 2004.

饶子和，南开大学校长，中国科学院院士，第三世界科学院院士。现任全国人大代表、中国科协常委、中国生物物理学会理事长、国际纯粹与应用生物物理联合会理事会执行理事、国家自然科学基金委“创新群体”学术带头人、生物学部咨询委员、国家973项目专家顾问组成员、国家重大研究计划（2006-2020）“蛋白质研究计划”专家组组长。主要从事与重要病毒和肿瘤相关的蛋白质结构、功能以及创新药物的研究，取得了一系列重要的原创性的研究成果，在SARS病毒、禽流感病毒和膜蛋白的三维结构与功能的研究中做出了突出贡献。在国际学术刊物上发表研究论文236篇，其中Nature/Cell系列论文13篇，包括Nature 3篇，Cell 2篇，被引用超过2000余次，同时申请及获发明专利18项。曾荣获求是杰出青年学者奖、何梁何利基金科学与技术奖、陈嘉庚科学奖、第三世界科学院最高奖——第里雅斯特科学奖、谈家桢生命科学成就奖、英国教育机构颁发的“杰出学术领袖奖”等奖项。

Dr. Patrick Brown is a professor in the Department of Biochemistry at Stanford University School of Medicine and an Investigator of the Howard Hughes Medical Institute. His BA (chemistry) is from the University of Chicago (1976). He received his MD and a PhD (biochemistry) for studies of DNA topoisomerases with Nick Cozzarelli, also from the University of Chicago. He completed a residency in pediatrics at Children’s Memorial Hospital (Chicago). As a post-doc with Mike Bishop and Harold Varmus, at the University of California, San Francisco, Brown developed the first biochemical system for studying how retroviruses like HIV integrate their own genes into the cells they infect and defined the fundamental features of this process. In 1988, he joined the Department of Biochemistry, Stanford University School of Medicine, as an assistant professor and an investigator of the Howard Hughes Medical Institute. At Stanford, Brown and colleagues developed the first practical methods for making and using DNA microarrays – which allow the activity of all the genes in a genome to be quantitatively measured - and developed widely used methods for analyzing, visualizing and interpreting global gene expression programs. By making his data and methods freely available he helped catalyze the development and application of genomic approaches to diverse medical and basic biological questions and diverse organisms. Brown pioneered the use of gene expression patterns to classify cancers and improve prediction of their clinical course. He has also played a leading role in making scientific and medical research literature freely available to scientists, physicians and the public around the world: with Harold Varmus and David Lipman, he developed the proposal that led to PubMed Central.   With Varmus and Michael Eisen, he founded the Public Library of Science, an innovative non-profit, open-access publisher of leading journals in biology and medicine, which make every article they publish immediately and freely available to the World. He is a member of the US National Academy of Sciences and Institute of Medicine. Honors include the American Cancer Society’s medal of honor for research, the Curt Stern Award of the American Society for Human Genetics, the Takeda Foundation Award and the National Academy of Sciences award for molecular biology. He is married to Sue Klapholz, MD, PhD and father of Zach, Ariel and Isaac Klapholz-Brown.

Zixin DENG, Professor of microbiology, and the heads of the School of Life Sciences and Biotechnology, and the Chinese Ministry of Education Key Laboratory of Microbial Metabolism at Shanghai Jiaotong University, Shanghai, China, a Member of Chinese Academy of Sciences, a Fellow of the Science Academy for the Developing World (formally the Third World Academy of Sciences, TWAS), and a Fellow of the American Academy of Microbiology. He was born in Hubei Province, China in 1957. He received his Bs degree on microbiology from Huazhong Agricultural University, Wuhan, China, in 1982, and a PhD degree on microbial genetics from the University of East Anglia, UK, in 1987, while working in Streptomyces group at John Innes Centre. Major interest is on Streptomyces genetics, biochemistry and molecular biology of antibiotic biosynthesis, and DNA backbone modification by sulfur (phosphorothiolation).

邓子新，中国科学院院士，第三世界科学院院士，美国微生物科学院院士。现任教育部微生物代谢重点实验室主任。担任中国农业生物技术学会副理事长、国际工业微生物遗传学组织专家委员会委员、国家973项目首席科学家、国家863计划领域专家组成员、国家自然科学基金委员会生命科学部第四届专家咨询委员会委员和学科评审组成员等职。任《Chemistry & Biology》，《BMC Microbiology》等数十个国内外刊物编辑或编委。长期从事微生物代谢的分子生物学研究，主攻放线菌遗传学及抗生素生物合成的化学生物学，打开DNA硫化修饰新领域，在国内外学术刊物上发表100余篇研究论文。先后获得国家自然科学二等奖、上海市和农业部科技进步一等奖、教育部自然科学二等奖、瑞典国王Baudiouin奖、霍英东基金会“青年教师奖”、首届国家杰出青年科学基金、“中国青年科技奖”(1994)、上海市十大科技创新英才、上海市科技领军人物、上海市劳动模范、全国五一劳动奖章、全国先进工作者等奖项。被授予国家级有突出贡献的专家称号。

Dr. Gang Bao is Robert A. Milton Chair Professor of Biomedical Engineering and a College of Engineering Distinguished Professor in the Department of Biomedical Engineering, Georgia Institute of Technology and Emory University. He is Director of the NHLBI Program of Excellence in Nanotechnology at Emory University and Georgia Tech, and Director of the NIH Nanomedicine Development Center at Georgia Tech. Dr. Bao received his Bachelor’s and Master’s degrees from Shandong University in China, and his PhD in Applied Mathematics from Lehigh University. He is a Fellow of the American Association of Advancement in Science (AAAS), a Fellow of the American Society of Mechanical Engineers (ASME), a Fellow of the American Physical Society (APS), and a Fellow of the American Institute for Medical and Biological Engineering.

Dr. Bao’s current research is focused on the development of nanotechnology and biomolecular engineering tools for biological and disease studies, including molecular beacons, magnetic nanoparticle probes, quantum dot bioconjugates, activitable molecular probes, and protein tagging/targeting methods. These approaches have been applied to cancer research, the analysis and detection of plaque formation in cardiovascular disease, viral infection detection, and the studies of nucleoprotein machines.

Prof. Songgang LI is currently associate director of BGI-Shenzhen, China. Prof. LI acquired his master degree of ecology and graduated from Dept. of Biology, Peking University in 1984. He went to UCLA in 1992 and attended in advanced studies of biology. He was appointed professor and associate dean of College of Life Sciences, Peking University. He spent more than twenty years in biology teaching and research. After early studies of computer simulation of ecological systems, he dedicated himself to bioinformatics research in recent years. He devoted himself to rice genomics and its analysis, including genome assembly, annotation as well as related methodology development such as the sequence assembler and alignment tools. Also, he was in charge of bioinformatics research in many international projects, such as silkworm, chicken and the first asian individual genome. As a famous professor of biology, he has supervised over 20 PhD students and master students. As a respected researcher, he has already published more than 40 peer-reviewed articles in high impact journals, such as Nature, Nature Genetics, Science, PloS Biology, Genome Research.

李松岗，教授，博士生导师，深圳华大基因研究院副院长。1984年毕业于北京大学生物系，曾任北京大学生命科学院副院长。从事生物信息学研究工作多年，曾参与水稻基因组测序、拼接、信息学分析工作，对完成水稻基因组项目做出重要贡献，还作为家蚕、家鸡、炎黄计划等多个项目生物信息主要负责人，指导完成多个项目的基因组生物信息学分析。拥有丰富的教学和科研工作经验，从教二十多年来先后指导过10名博士生、6名硕士生。在国际知名期刊上发表的学术论文共四十余篇，2002年出版的学术专著《实用生物统计学》被评为北京市精品教材。

Dr. Gregory Stephanopoulos is currently the W.H. Dow Professor of Chemical Engineering and Biotechnology at MIT, Instructor of Bioengineering at Harvard Medical School, and the Taplin Professor of HST. He taught at Caltech (1978-85) before joining MIT in 1985. His research interest focuses on metabolic engineering, the engineering of microbes for the production of fuels and chemicals. He has co-authored or –edited 5 books, more than 320 papers and 30 patents and supervised more than 110 graduate and post-doctoral students. He is presently the editor-in-chief of Metabolic Engineering and serves on the Editorial Boards of 7 scientific journals and the Advisory Boards of 5 ChE departments. He has been recognized with numerous awards (Dreyfus, Excellence in Teaching-Caltech, AIChE Technical Achievement Award, PYI, AIChE-FPBE Division Award, M.J. Johnson Award of ACS, Merck Award in Metabolic Engineering, the R.H. Wilhelm Award in Chemical Reaction Engineering of AIChE, Amgen Award in Biochemical Engineering). In 2002 he was elected to the AIChE Board of Directors, in 2003 to the National Academy of Engineering (NAE) and in 2005 was awarded the doctor technices honoris causa by the Technical University of Denmark. In 2007 he won the C. Thom Award from SIM and the Founders Award from AIChE, and in 2010 the ACS E.V. Murphree Award in Industrial and Engineering Chemistry. Professor Stephanopoulos has taught undergraduate and graduate courses of the core of Chemical Engineering and Biotechnology at Caltech and MIT and co-authored the first textbook on Metabolic Engineering. He is presently directing a research group of approximately 25 researchers.

Dr. Yongzhang Luo was born in 1962 in Yantai, Shandong Province. He graduated with a B.S. degree from Lanzhou University in 1985 and obtained his Ph.D degree from the Department of Molecular and Cellular Biology at the University of California, Berkeley, in 1993. After postdoctoral training at Harvard University and Stanford University, he went back to China in 1999, and joined Yantai Medgenn Co., Ltd. as the chief scientist. In 2001, Dr. Luo was appointed as the Professor-in-Charge of the “100 talents Programme” of Tsinghua University and the professor of the “Chueng Kong Scholars Programme.” He is now a professor in the School of Life Sciences at Tsinghua University, the director of the National Engineering Laboratory for Anti-tumor Protein Therapeutics, the vice president of the Chinese Protein Society. He is an associate editor of BMC Cell Biology, an editorial board member of Oncology Research, Genes & Cancer, and Chinese Clinical Oncology, respectively.

罗永章，1962年出生于山东省烟台市。1985年获兰州大学化学系学士学位；1993年获美国加州大学伯克利分校分子与细胞生物学系博士学位。1993至1998年，先后在美国哈佛大学和斯坦福大学从事博士后研究。1999年回国创业，担任原山东烟台麦得津生物工程股份有限公司首席科学家。2001年，受聘于清华大学“百名人才引进计划”责任教授，同年被聘为“长江学者特聘教授”。现任清华大学生命科学学院教授、抗肿瘤蛋白质药物国家工程实验室主任、中国生物化学与分子生物学会蛋白质专业委员会副主任委员。同时，兼任《BMC Cell Biology》副主编，《Oncology Research》、《Genes & Cancer》和《临床肿瘤学杂志》编委。

 

 

Henry H. Sun, PhD., Professor. Former highest ranked Expert Scientist / Reviewer of the FDA and a member of the Federal Asian Executives of the United States. Dr. Sun currently serving as the Vice President of Tasly Group, President of Tasly Pharmaceuticals, Board of Directors of Tasly-Coop Pharmaceuticals, Co. Ltd., Special Professor of School of Medicine of Nottingham University, Adjunct Principal Investigator of China Academy of Science, and Professor and Department Chair at School of Pharmaceutical Science and Technology, Tianjin University.

Dr. Sun graduate from Shanghai Medical University in 1982, and received his Ph.D. in Clinical Pharmacology and Biopharmaceutics from the University of Connecticut in 1993. Dr. Sun then joint the FDA responsible for decision-making in IND/NDA reviews, leading the generation of regulatory policy and ICH guidance, and leading the pharmacometrics programs that supports the R&D of new drugs. Dr. Sun started to serve his new positions in China since 2006.

Over the past 25 years, Dr. Sun was granted and completed 17 national research projects in the USA, Europe, and China. Dr. Sun is very experienced and highly achieved in the fields of science, regulation, and management. Dr. Sun provided critical strategic advises and guidance for the Federal Governments and numerous international giant pharmaceutical enterprises. His current interests are the development of innovative medical products, and research in regulatory policy, clinical pharmacology, and translational medicine.

孙鹤，教授、博士生导师。原任美国食品药品监督管理总局首席科学家和评审官。现任天津天士力集团副总裁、天士力北美药业有限公司总经理、美国国家卫生研究院（NIH）特邀科学家、英国诺丁汉大学医学院、上海复旦大学医学院特聘教授、天津大学药学院教授兼系主任等职。孙鹤博士1982年毕业于上海医科大学，1993年获美国康涅狄格大学临床药理学博士，随后进入美国食品药品监督管理局（FDA），负责新药评审管理决策，在临床药理和计量药理学领域提供学术顾问指导，参于全球药政协调化，主持或参与制定药政法规管理政策等。由于在科学与法规方面的特殊贡献，成为FDA最高级别的首席科学家/评审专家之一。在近十年间，孙鹤博士先后提出、承担和完成了十七项国家重大科研课题，并为全球知名企业及政府提供关键性战略计划和指导。

Dr.Sean Simpson is the Chief Scientific Officer and a Founder of LanzaTech.Sean holds a PhD from York University, UK, and a Masters degree from Nottingham University, UK. Prior to LanzaTech, Sean had eight years experience in bio-products development. Including operating a cell culture facility and developing a pilot plant with Hoffmann La-Roche in Basel, Switzerland, health biologics with Sandoz Forschungsinstitute, Vienna, Austria, working on crop biologics with the Japan International Research Centre for Agricultural Sciences, Tsukuba, Japan, and most recently, pioneering a process for ethanol production from hardwood with Genesis R&D Corporation in New Zealand. The latter has since been spun out by Genesis R&D and established as a stand-alone company called BioJoule.

Sean Simpson博士, LanzaTech公司首席科学官（CSO）和创始人。Sean Simpson博士在生物燃料的开发和生产等多项技术领域享有盛誉，创办LanzaTech公司之前，拥有长达8年的生物产品研发经验，曾主导运营过细胞培殖机构，在瑞士巴塞尔的罗氏公司（Hoffmann La-Roche）建立过实验工厂，在奥地利维也纳的Sandoz Forschungs学院研究健康生物制剂，在日本筑波市的农业科学国际研究中心研究农作物生物制剂,在新西兰Genesis研发公司领导以硬木纤维素为原料的生物乙醇生产项目，该项目后被剥离出来单独成立BioJoule公司。